Blogs

Pharmaceutical packaging is a critical component of product quality, regulatory compliance, and patient safety. Its role extends far beyond containment, acting as a protective barrier that maintains sterility, stability, and efficacy throughout the product’s lifecycle. From early development and clinical trials to commercial manufacturing, distribution, and final patient use, packaging systems are exposed to multiple risks that can compromise integrity if not properly controlled.

Regulatory bodies such as the FDA and guidance frameworks like USP <1207> increasingly emphasise the need for deterministic container closure integrity testing (CCIT) across the entire lifecycle. At PTI, packaging integrity is treated as a continuous, science-driven quality process rather than a final-stage inspection activity.

Why Packaging Integrity Testing Is Essential During Different Stages of the Product Lifecycle

Pharmaceutical products encounter different stress conditions as they move from development to patient delivery. A container closure system that performs well in one stage may fail in another if integrity is not consistently verified.

Packaging integrity testing is essential because it helps identify and control risks such as:

• Seal defects introduced during scale-up or high-speed manufacturing.
• Microleaks caused by material incompatibility or closure misalignment.
• Integrity degradation due to transportation, pressure changes, or long-term storage

By applying CCIT at defined lifecycle stages, manufacturers can proactively detect integrity issues, reduce product loss, and maintain compliance with global regulatory expectations.

1. Packaging Development and Design

The packaging lifecycle begins with development and design, where container materials, closure components, and sealing mechanisms are selected and evaluated. Decisions made at this stage directly influence long-term package performance. Integrity risks during development typically relate to material compatibility, seal geometry, and dimensional variability. These risks may not be visible using traditional visual or probabilistic testing methods.

PTI supports early-stage development by applying deterministic CCIT technologies, such as Vacuum Decay, to evaluate package integrity in a non-destructive and quantitative manner. This allows development teams to:

• Compare container closure systems using measurable integrity data.
• Identify potential failure modes early in the design process.
• Establish baseline integrity performance before advancing to clinical studies.

This data-driven approach reduces late-stage redesigns and supports more robust packaging selection.

2. Clinical Trials and Validation

During clinical trials, pharmaceutical packaging is exposed to real-world handling, transportation, and storage conditions. Even small integrity failures at this stage can compromise clinical data, delay regulatory submissions, or increase development costs.

Regulators increasingly expect integrity testing methods used during clinical phases to be deterministic, validated, and scientifically justified. USP <1207> highlights the limitations of probabilistic methods and supports technologies that provide consistent detection limits and repeatable results.

PTI assists with feasibility studies, test method development, and validation activities to ensure that CCIT methods are appropriate for the product and packaging system. High Voltage Leak Detection (HVLD) is commonly used for liquid-filled parenteral products during clinical trials due to its high sensitivity and non-destructive nature.

3. Scale-Up and Commercial Manufacturing

As products transition to commercial manufacturing, packaging systems face new challenges associated with higher production volumes and increased process complexity. Seal variability, equipment differences, and higher line speeds can introduce defects that may not be detected through limited sampling.

PTI’s deterministic CCIT solutions are designed for both at-line and inline inspection, supporting integrity assurance in production environments. In commercial manufacturing, CCIT helps manufacturers:

• Detect process drift before it leads to batch failure.
• Reduce reliance on destructive, subjective test methods.
• Generate robust data for regulatory inspections and audits.

4. Distribution, Storage, and Transportation

Once released, pharmaceutical products must maintain package integrity throughout distribution and storage. Environmental factors such as temperature changes, pressure fluctuations during air transport, and mechanical stress can compromise seals over time.

Integrity risks during this stage often include:

• Gradual loss of sterility due to microleaks.
• Oxygen ingress affecting product stability.
• Seal degradation during long-term storage.

PTI supports integrity testing as part of stability studies and transportation simulation programmes. Vacuum Decay technology allows manufacturers to assess package robustness under simulated distribution conditions without damaging the package, ensuring continued protection throughout the supply chain.

5. Patient Delivery and Use

The final stage of the packaging lifecycle is patient delivery, where package integrity has a direct impact on patient safety and treatment effectiveness. Any breach in integrity at this stage can lead to contamination, reduced efficacy, or adverse patient outcomes.

PTI’s lifecycle-based integrity strategy ensures that packaging performance is continuously verified rather than assumed. By applying deterministic CCIT methods at multiple lifecycle stages, manufacturers gain confidence that the product remains protected until the point of use.

Conclusion

Pharmaceutical packaging integrity must be managed across the entire product lifecycle, not verified at a single endpoint. Each stage, from development and clinical validation to manufacturing, distribution, and patient use, introduces unique risks that require scientifically validated solutions.

PTI’s expertise in container closure integrity testing (CCIT) and its deterministic technologies, including HVLD and Vacuum Decay, enable pharmaceutical manufacturers to implement a proactive, data-driven approach to packaging quality. By embedding integrity testing throughout the lifecycle, companies can strengthen regulatory compliance, reduce risk, and protect patient safety.

Container Closure Integrity (CCI) is a critical quality attribute across the entire life sciences product lifecycle. From early formulation work to large-scale commercial manufacturing, package integrity directly impacts product sterility, stability, patient safety, and regulatory compliance. Regulatory bodies, including the FDA and EMA, reinforced by USP <1207>, now expect deterministic, validated, and lifecycle-based CCI strategies rather than legacy probabilistic methods.

PTI supports pharmaceutical, biotech, and medical device manufacturers worldwide with a science-driven, lifecycle-focused approach to packaging integrity. By combining deterministic CCI technologies, method development expertise, and global testing services, PTI enables manufacturers to build, validate, and maintain package integrity from R&D through routine production and post-market lifecycle management.

Early R&D: Building Integrity into Package Design

Packaging integrity must be engineered into the package system from the earliest stages of development. Decisions made during R&D, such as container material, closure system, sealing method, and fill volume, directly influence long-term integrity performance.

PTI supports early-stage development by helping teams understand how design variables affect seal quality and defect formation. Using deterministic CCI technologies, PTI enables R&D teams to identify marginal seals, microleaks, and material weaknesses before designs are locked in.

Key PTI contributions during early R&D include:

• Feasibility studies for vials, prefilled syringes, BFS containers, cartridges, blister packs, pouches, and bottles
• Quantitative evaluation of seal integrity and leak sensitivity
• Data-driven comparison of alternative package designs and materials

By generating objective integrity data at this stage, PTI helps manufacturers avoid costly redesigns, reduce development timelines, and ensure that integrity performance aligns with regulatory and production requirements.

Method Development: Selecting the Right CCI Strategy

Once a package system is defined, selecting an appropriate CCI method becomes critical. USP <1207> emphasises that CCI methods must be deterministic, quantitative, and suitable for the specific package-product combination.

PTI specialises in CCI method development using its portfolio of deterministic technologies, including:

• Vacuum Decay Technology for non-porous and flexible packaging
• High Voltage Leak Detection (HVLD) for liquid-filled parenteral products
• Helium Leak Detection for parenterals and other pharma packaging formats

PTI’s method development process focuses on:

• Establishing measurable detection limits
• Correlating leak size to package risk
• Ensuring method repeatability and robustness

This approach ensures that the selected CCI method is not only technically sound but also aligned with regulatory expectations across global markets, including the US, EU, and emerging life sciences hubs such as India and Southeast Asia.

Validation and Qualification: Ensuring Regulatory Compliance

Validation is a pivotal stage where CCI testing transitions from development to regulated quality control. Regulatory agencies expect documented evidence that the selected CCI method is capable, repeatable, and suitable for its intended use.

PTI supports full CCI method validation and equipment qualification, aligned with USP <1207>, FDA guidance, and global GMP standards. Validation activities are structured to withstand regulatory scrutiny during audits and inspections.

PTI’s validation support includes:

• Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ)
• Detection limit studies using calibrated defects
• Method robustness and repeatability assessments
• Documentation support aligned with global regulatory submissions

Commercial Production: Reliable CCI in Routine Quality Control

In commercial production, CCI testing must deliver consistent, high-throughput results without compromising sensitivity or reliability. Manual, subjective methods such as dye ingress are increasingly inadequate for modern pharmaceutical manufacturing environments.

PTI’s deterministic CCI systems are designed for routine quality control, supporting both offline laboratory testing and at-line or in-line inspection applications. These systems provide objective, quantitative results that reduce operator dependency and variability.

Benefits of PTI CCI solutions in production environments include:

• Non-destructive testing, preserving valuable product
• Faster test cycles suitable for high-volume manufacturing
• Clear pass/fail criteria with data traceability
• Reduced risk of false positives and false negatives

This reliability is particularly critical for sterile injectables, biologics, and combination products, where integrity failures can lead to recalls, regulatory action, and patient safety risks.

Lifecycle Management: Ongoing Integrity Assurance

Packaging integrity does not end at product launch. Changes in materials, suppliers, processes, or scale can impact package performance over time. Regulatory agencies expect manufacturers to demonstrate continued control of CCI throughout the product lifecycle.

PTI supports ongoing lifecycle management by enabling manufacturers to monitor integrity trends, reassess methods when changes occur, and support post-market investigations when needed. Lifecycle support includes:

• Periodic method requalification
• Support for change control and comparability studies
• Failure investigations and root cause analysis
• Long-term data trending for continuous improvement

This proactive approach ensures that packaging integrity remains robust throughout commercial life, regardless of geographic manufacturing expansion or evolving regulatory expectations.

Conclusion

From early R&D through commercial production and lifecycle management, PTI provides a comprehensive, science-based approach to packaging integrity. By leveraging deterministic CCI technologies, method development expertise, and global service capabilities, PTI enables life sciences manufacturers to meet regulatory expectations, protect patients, and maintain product quality across all stages of the packaging lifecycle.

For companies operating in regulated markets worldwide, including the United States, Europe, India, and the Asia-Pacific region, PTI’s lifecycle-driven CCI strategy delivers confidence, compliance, and consistency from development to delivery.

Container Closure Integrity (CCI) testing is a critical quality requirement for parenteral products, where even microscopic leaks can compromise sterility and patient safety. Regulatory agencies such as the FDA and guidance documents like USP <1207> emphasise the need for deterministic, validated CCI methods that provide consistent and measurable results throughout the product lifecycle.

Parenteral drug products, including injectables, biologics, and vaccines, present unique integrity testing challenges due to their complex container systems and stringent leak rate requirements. PTI addresses these challenges through its High Voltage Leak Detection (HVLD) technology, a non-destructive, deterministic CCI solution specifically designed for liquid-filled parenteral packaging.

Parenteral Products: Key CCI Testing Challenges

• Extremely Tight Leak Detection Requirements: Parenteral products require detection of leaks at the micron and sub-micron level. Conventional probabilistic methods, such as dye ingress or microbial ingress testing, often struggle to consistently detect defects of this size. These methods also lack quantitative outputs, making it difficult to establish clear detection limits.
• Complex Container Closure Systems: Parenteral packaging formats, including glass vials, pre-filled syringes, cartridges, and BFS containers, introduce multiple potential leak paths. Defects may occur at the stopper interface, crimp seal, plunger interface, or within the container itself. Accurately identifying these defects requires a technology capable of evaluating the entire container closure system.
• Destructive Testing Limitations: Many traditional CCI methods require destructive testing, which increases product waste and restricts sample sizes. Destructive approaches also prevent manufacturers from implementing 100% inspection and limit the ability to perform in-line testing during routine production.
• Regulatory Expectations for Deterministic Methods: Regulatory authorities increasingly favour deterministic CCI technologies that offer known sensitivity, reproducibility, and validated performance. Meeting these expectations using legacy methods often requires extensive justification and supplemental testing.

Non-Destructive CCI Testing Using PTI’s HVLD Technology

HVLD technology is a non-destructive and non-invasive Container Closure Integrity Test (CCIT) method that utilises controlled voltage characteristics to inspect a wide range of parenteral products, including complex combination products. The technology is suitable for pre-filled syringes, vials, cartridges, ampoules, BFS containers, bottles, and pouches.

The HVLD test method accurately detects and localises defects such as pinholes, micro-cracks, stopper or plunger leaks, non-visible leaks beneath crimp seals, and other integrity failures that may compromise sterility. To verify container closure integrity, the system scans a sealed, non-conductive container using precision electrode probes. When a defect is present, a change in electrical resistance occurs, altering the current flow and allowing the system to identify the breach.

Unlike conventional high-voltage leak detection approaches, PTI’s HVLD technology operates at significantly lower voltage levels, using approximately 50% less voltage and exposing the product and surrounding environment to less than 5% of that applied voltage. This reduced exposure minimises potential product risk while also significantly lowering ozone generation during testing. As one of the most sensitive deterministic CCI technologies available, PTI’s HVLD solution is particularly well suited for high-risk parenteral and combination product applications.

Benefits of PTI’s HVLD Technology for Parenteral CCI Testing

• Non-Destructive, Automated Inspection Capability: PTI’s HVLD technology enables full-unit inspection without damaging the product, allowing manufacturers to implement 100% testing while reducing waste and improving batch-level confidence.
• Deterministic, High-Sensitivity Detection: The technology delivers quantitative, repeatable results with sensitivity at the micron level. Clearly defined detection limits, supported by validated positive controls, strengthen method validation and regulatory submissions.
• Production-Ready and Regulatory Aligned: HVLD supports automated testing in manufacturing environments and aligns with USP <1207> expectations. Its deterministic performance simplifies validation, system suitability testing, and ongoing integrity verification while reducing operator dependence.

Conclusion

CCI testing for parenteral products demands technologies that deliver high sensitivity, repeatability, and regulatory compliance without compromising product integrity. Traditional destructive and probabilistic methods often fall short of meeting modern industry and regulatory expectations.

PTI’s High Voltage Leak Detection (HVLD) technology provides a proven, non-destructive, deterministic solution for liquid-filled parenteral packaging. By enabling high-sensitivity leak detection, scalable to be fully automated, and strong regulatory alignment, PTI’s HVLD systems help pharmaceutical manufacturers strengthen sterility assurance, reduce risk, and maintain product quality throughout the product lifecycle.

Ensuring that pharmaceutical products remain safe, sterile, and stable throughout their lifecycle is one of the most critical responsibilities in the life sciences industry. As therapies become more sensitive—ranging from biologics and vaccines to advanced injectables and cell & gene therapies—the role of Container Closure Integrity (CCI) has grown significantly. A failure in CCI can lead to contamination, loss of sterility, compromised efficacy, and potentially life-threatening consequences for patients.

This is why regulatory bodies such as the FDA, EMA, and USP continuously reinforce the need for robust, reliable, and science-based CCI testing methods. With the industry moving toward deterministic, non-destructive solutions, companies like PTI are advancing the field by providing high-precision technologies suitable for both lab and production environments.

Why CCI Testing Matters in Life Sciences

1. Protecting Product Sterility

Sterile products—including parenterals, vaccines, and biologics—must remain free from microbial contamination. Even the slightest breach in a container’s sealing interface can allow microorganisms or particulates to enter. CCI testing ensures that the container closure system maintains its protective barrier throughout manufacturing, storage, and distribution.

2. Safeguarding Drug Efficacy

Many modern drug formulations are highly sensitive to environmental factors such as oxygen, moisture, and CO2. A compromised closure system can alter the product’s chemical composition, degrade active ingredients, or destabilize formulations. CCI testing verifies that the packaging system prevents gas or vapor ingress, preserving potency from production to administration.

3. Meeting Global Regulatory Requirements

Regulatory agencies require manufacturers to demonstrate that their container closure systems ensure safety and sterility. Guidance documents such as USP <1207> mandate the use of deterministic technologies—methods with quantifiable outputs, validated accuracy, and scientific reliability. CCI testing supports compliance with:

• cGMP guidelines
• FDA requirements for parenteral products
• EU Annex 1 for sterile manufacturing

4. Reducing Patient Safety Risks

Failed CCI can lead to serious patient harm—severe infections, reduced therapeutic effect, or adverse immune responses. By implementing robust CCI testing, manufacturers reduce risks and enhance overall product quality and safety.

5. Avoiding Costly Recalls and Liability

Loss of sterility is among the top causes of pharmaceutical recalls. CCI failures discovered late in the lifecycle—especially after commercial distribution—result in extensive financial losses, legal exposure, and damage to a brand’s reputation. Deterministic CCI testing helps detect issues early, preventing such outcomes.

Life Sciences Package Integrity Testing Solutions Offered by PTI

PTI is a global leader in non-destructive, deterministic CCI technologies. Their solutions are designed to support R&D, stability studies, routine QC testing, and high-throughput production applications across the life sciences sector. Below are PTI’s key CCI testing technologies widely adopted for inspecting vials, syringes, cartridges, IV bags, BFS containers, and other sterile products.

1. Vacuum Decay Technology

Vacuum Decay is one of PTI’s most widely used deterministic methods for Container Closure Integrity testing (CCIT). It is a non-destructive technique that measures pressure changes inside a sealed test chamber to identify leaks in pharmaceutical containers. During the test, the container is placed inside the chamber, and a controlled vacuum is applied. If there is any defect—such as a crack, pinhole, or channel leak—air will escape from the container, causing a detectable rise in pressure. Because the system uses highly sensitive pressure transducers, it can identify extremely small leaks with high accuracy and repeatability. Vacuum Decay is suitable for a wide range of life sciences packaging formats, including vials, syringes, cartridges, ampoules, and blister packs. It is fully aligned with USP <1207> recommendations and is widely used for stability studies, lab testing, and automated in-line inspection.

2. High Voltage Leak Detection (HVLD)

High Voltage Leak Detection is a non-destructive electrical conductivity-based method specifically designed for liquid-filled pharmaceutical products. In this technique, a high-voltage potential is applied across the container. If the container has any micro-channel or defect, the liquid inside forms a conductive path and creates a measurable electrical response. This allows the system to detect even very small leaks that may not be visible through other inspection methods. HVLD is ideal for prefilled syringes, glass vials, cartridges, IV bags, and blow-fill-seal containers. It is fast, sensitive, and capable of handling products with complex shapes or high-value formulations. Because HVLD can be integrated into both lab environments and 100% in-line production systems, it is widely used for ensuring product sterility and regulatory compliance across the life sciences industry.

Conclusion

Container Closure Integrity is a foundational element of safe and reliable pharmaceutical packaging. In an industry where even the smallest leak can compromise sterility, efficacy, and patient trust, CCI testing serves as a critical safeguard for product quality. As regulatory expectations shift toward deterministic, science-driven methods, manufacturers must adopt advanced technologies capable of delivering quantitative, repeatable results.

PTI’s portfolio—including Vacuum Decay and High Voltage Leak Detection (HVLD)—provides life sciences companies with world-class solutions that support robust CCI programs across the product lifecycle. Whether in R&D, quality control, or commercial production, these technologies ensure that every package meets the highest standards of safety, performance, and regulatory compliance.

In regulated industries such as pharmaceuticals, biologics, and medical devices, packaging integrity is inseparable from product quality and patient safety. Regulatory authorities expect manufacturers to verify container closure integrity (CCI) using scientifically validated, deterministic, and globally accepted test methods. PTI has built its entire technology portfolio around these expectations, ensuring full alignment with ASTM standards, USP <1207>, and international regulatory frameworks. PTI’s commitment to deterministic and data-driven testing makes its platforms the preferred choice for manufacturers looking to strengthen compliance and quality assurance.

Overview of ASTM Methods Relevant to Packaging Integrity

ASTM International provides a set of rigorous methods that define how packaging integrity should be evaluated. PTI’s technologies are engineered to operate precisely within the parameters established by these standards, ensuring that results are meaningful, and repeatable.

1. ASTM F2338 – Vacuum Decay Testing

ASTM F2338 is one of the most widely recognized deterministic standards for non-destructive leak detection, especially for rigid and semi-rigid containers. This test method originally established in 2003 was developed using PTI VeriPac instruments. The method uses pressure differentials to quantify even very small leak pathways, making it suitable for sterile products, stability studies, and routine quality control. Vacuum Decay is valued in the industry because it provides objective, numerical data and eliminates the subjectivity of traditional probabilistic tests.

2. ASTM F2391 – Helium Leak Detection

ASTM F2391provides guidance for using helium mass spectrometry as an ultra-sensitive CCI technique. This method is typically used during development, validation, and feasibility studies when extremely tight sensitivity—down to 10?¹° mbar·L/s—is required. Helium-based methods are especially relevant for complex drug–device platforms, high-value biologics, and packaging systems that require the highest level of integrity assurance.

3. ASTM F3004 – Airborne Ultrasound Seal Integrity Evaluation

ASTM F3004 defines a non-destructive approach for evaluating the seal integrity of flexible packages. Ultrasonic inspection technology, which this standard is based on, generates high-resolution images of the seal area and can detect defects such as channels, inclusions, wrinkles, or weak seals. These are issues that often remain undetected through visual inspection or conventional destructive tests, making ASTM F3004 important for flexible packaging used across pharmaceutical and medical device applications.

Role of PTI Technologies in Supporting Compliance

PTI’s CCI solutions are designed to fit within the compliance expectations set by global regulatory authorities. By offering deterministic methods aligned with ASTM and USP standards, PTI helps manufacturers establish a robust, defensible quality framework.

PTI technologies integrate seamlessly into compliance structures defined by:

• USP <1207>, which prioritizes deterministic test methods over probabilistic approaches
• FDA guidance on CCI testing and sterility assurance
• EU Annex 1, particularly the 2023 revision emphasizing improved control over container integrity
• ISO 11607 for medical device packaging integrity
• ICH Q9 and Q10, which frame risk-based quality management

Beyond method alignment, PTI systems incorporate advanced data integrity controls—secure audit trails, encrypted electronic records, and role-based access—supporting 21 CFR Part 11 requirements. These capabilities ensure that packaging integrity results are reliable, traceable, and fully compliant during regulatory inspections.

PTI also plays a crucial role in method lifecycle support. Its application engineers assist manufacturers in method development, feasibility studies, and validation activities (IQ/OQ/PQ), ensuring that each method meets the sensitivity and repeatability expectations laid out in global guidelines. This partnership-oriented approach is particularly valuable for companies dealing with new and complex container systems, or high-value biologics.

The Importance of Standardization in CCI Testing

Standardization forms the backbone of modern quality systems. Without standardized, deterministic methods, manufacturers risk variability, inconsistent results, and regulatory observations. ASTM standards provide a common scientific foundation, enabling manufacturers around the world to evaluate packaging using uniform criteria.

Standardization strengthens:

• Test reproducibility across sites
• Regulatory acceptance of data
• Risk mitigation for sterility failures
• Packaging development and optimization
• Overall product safety and lifecycle quality

PTI contributes to this ecosystem by designing technologies that comply with the most trusted global standards while actively participating in the evolution of CCI science. PTI’s research, industry collaborations, and continuous technological innovation help shape best practices that are now widely adopted across the pharmaceutical packaging industry.

Conclusion

PTI’s technologies are engineered to meet the highest expectations of global regulatory authorities by aligning directly with ASTM methods, USP <1207> principles, and the requirements outlined in FDA and EU guidelines. By offering deterministic and quantitative solutions—including Vacuum Decay, Helium Leak Detection, HVLD, and Ultrasonic Seal Testing—PTI empowers manufacturers to ensure that their packaging systems maintain integrity throughout the product lifecycle. The combination of scientific rigor, regulatory alignment, and robust method development support makes PTI a trusted leader in the global package integrity testing space.